In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
SERIOUS NEUROPSYCHIATRIC EVENTS HAVE BEEN REPORTED IN PATIENTS TAKING MONTELUKAST
DISCUSS BENEFITS AND RISKS OF MONTELUKAST WITH PATIENTS AND CAREGIVERS
MONITOR FOR NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS TAKING MONTELUKAST
DISCONTINUE MONTELUKAST IMMEDIATELY IF NEUROPSYCHIATRIC SYMPTOMS OCCUR
BECAUSE THE BENEFITS OF MONTELUKAST MAY NOT OUTWEIGH THE POTENTIAL RISK OF NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH ALLERGIC RHINITIS, RESERVE USE FOR PATIENTS WHO HAVE AN INADEQUATE RESPONSE OR INTOLERANCE TO ALTERNATIVE THERAPIES
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.